Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis.
A research investigation to evaluate the potential of an oral preparation of Mycobacterium vaccae SRL172 (NCTC 11659) as an immunotherapeutic has been carried out in ten patients with moderate to advanced pulmonary tuberculosis at Carrasco Hospital, Argentina. Comparison was made between oral and injected M.vaccae sharing a mutual control group. Clinical, bacteriological, hematological, radiological and immunological assessments all showed comparable benefits for both injected and oral treatment over those achieved with chemotherapy alone. The only significant difference between results of injected and oral M.vaccae was the failure of the latter to reduce TNF-alpha production by cultured mononuclear cells. A more intensive regime for the oral preparation was used, which as an addition to the directly observed therapy, short-course, treatment should improve results in both drug susceptible and drug-resistant cases. A Phase II Good Clinical Practice trial is now required.
Dlugovitzky
Diana
D
Universidad Nacional de Rosario, Santa Fe, Rosario, Argentina.
Notario
Rodolfo
R
Martinel-Lamas
Diego
D
Fiorenza
Gladys
G
Farroni
Miguel
M
Bogue
Christina
C
Stanford
Cynthia
C
Stanford
John
J
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002478:Cells, Cultured / Q000378:metabolism; D017077:Culture Media, Conditioned / Q000737:chemistry; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D007271:Injections, Intradermal; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009161:Mycobacterium; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult
D001428:Bacterial Vaccines; D017077:Culture Media, Conditioned; D014409:Tumor Necrosis Factor-alpha; D015164:Vaccines, Inactivated; D007371:Interferon-gamma